• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

低位胃肠道肿瘤细胞减灭术后的静脉血栓栓塞事件

Venous thromboembolic events following cytoreductive surgery for lower gastrointestinal neoplasia.

作者信息

Guirgis Mina, Keelan Simon, McEntee Philip, Han Margaret, Moroz Paul

机构信息

Department of General Surgery, Joondalup Health Campus, Perth, Western Australia, Corner Grant Boulevard & Shenton Avenue, Joondalup, Western Australia, Australia, 6027.

Western Australian Peritonectomy Service, Joondalup Health Campus, Perth, Western Australia, Suite 24-26 Specialist Medical Centre East, Level 2 Joondalup Private Hospital, 60 Shenton Avenue, Joondalup, Western Australia, Australia, 6027.

出版信息

Surg Pract Sci. 2024 Jul 14;18:100257. doi: 10.1016/j.sipas.2024.100257. eCollection 2024 Sep.

DOI:10.1016/j.sipas.2024.100257
PMID:39845429
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11749419/
Abstract

INTRODUCTION

Cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IPC) represent a high-risk for venous thromboembolism (VTE) due to malignancy, prolonged surgery and immobility. We investigated the incidence of and risk factors for VTE following CRS/IPC.

MATERIALS AND METHODS

Data was analysed on 130 CRS/IPC performed over a 6-year period at a single centre, the Western Australian Peritonectomy Service (WAPS), on lower gastrointestinal neoplasia: pseudomyxoma peritoneii (PMP), colorectal cancer (CRC) and appendix cancer (AC). Data was analysed by univariate and multivariate logistic regression to identify risk factors for VTE.

RESULTS

31 patients (24 %) experienced a VTE. The percentages of VTE among patients with PMP ( = 50), CRC ( = 53) and AC ( = 27) were 36 %, 17 % and 15 % respectively. 60 % of these cases were asymptomatic. The odds of VTE were higher for PMP patients than in patients with a other histopathology (OR=2.9, = 0.01). Other significant risk factors for VTE on univariate analysis were PCI (OR=1.07, = 0.001), pelvic dissection (OR=5.52, = 0.001) and operation time (OR=1.36, = 0.001).

CONCLUSION

This study demonstrates high rates of VTE in patients undergoing CRS/IPC. Patients with PMP have a three-fold higher risk of VTE compared to other malignancies (CRC+AC). As most VTE cases were asymptomatic, aggressive early investigation and intervention is indicated for patients undergoing CRS/IPC.

摘要

引言

减瘤手术(CRS)和腹腔内化疗(IPC)因恶性肿瘤、手术时间延长和活动减少而具有静脉血栓栓塞(VTE)的高风险。我们调查了CRS/IPC后VTE的发生率及危险因素。

材料与方法

对西澳大利亚腹膜切除术服务中心(WAPS)在6年期间对130例下消化道肿瘤(腹膜假黏液瘤(PMP)、结直肠癌(CRC)和阑尾癌(AC))患者进行的CRS/IPC数据进行分析。通过单因素和多因素逻辑回归分析数据以确定VTE的危险因素。

结果

31例患者(24%)发生VTE。PMP患者(n = 50)、CRC患者(n = 53)和AC患者(n = 27)中VTE的发生率分别为36%、17%和15%。这些病例中有60%无症状。PMP患者发生VTE的几率高于其他组织病理学患者(OR = 2.9,P = 0.01)。单因素分析中其他VTE的显著危险因素为PCI(OR = 1.07,P = 0.001)、盆腔清扫术(OR = 5.52,P = 0.001)和手术时间(OR = 1.36,P = 0.001)。

结论

本研究表明接受CRS/IPC的患者VTE发生率较高。与其他恶性肿瘤(CRC+AC)相比,PMP患者发生VTE的风险高三倍。由于大多数VTE病例无症状,对于接受CRS/IPC的患者,应积极进行早期检查和干预。

相似文献

1
Venous thromboembolic events following cytoreductive surgery for lower gastrointestinal neoplasia.低位胃肠道肿瘤细胞减灭术后的静脉血栓栓塞事件
Surg Pract Sci. 2024 Jul 14;18:100257. doi: 10.1016/j.sipas.2024.100257. eCollection 2024 Sep.
2
Western Australian Peritonectomy Service: a review of the first 6 years of operation of a low-volume peritonectomy centre.西澳大利亚腹膜切除术服务:一个低容量腹膜切除中心运营的头 6 年回顾。
ANZ J Surg. 2021 May;91(5):885-889. doi: 10.1111/ans.16627. Epub 2021 Feb 15.
3
Long-term survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Waikato, Aotearoa New Zealand: a 12-year experience.在新西兰怀卡托行细胞减灭术和腹腔内热化疗后的长期生存:12 年经验。
ANZ J Surg. 2024 Apr;94(4):621-627. doi: 10.1111/ans.18777. Epub 2023 Nov 22.
4
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.阑尾来源的假性黏液瘤行细胞减灭术(CRS)和腹腔内热灌注化疗(HIPEC):单中心研究结果。
Updates Surg. 2020 Dec;72(4):1207-1212. doi: 10.1007/s13304-020-00788-5. Epub 2020 May 14.
5
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei and Appendix Tumours.减瘤手术与热灌注腹腔化疗治疗腹膜假黏液瘤和阑尾肿瘤
Indian J Surg Oncol. 2016 Jun;7(2):166-76. doi: 10.1007/s13193-015-0478-9. Epub 2015 Oct 24.
6
An observational cohort of patients with colorectal peritoneal metastases or pseudomyxoma peritonei treated with CRS-HIPEC: Development and first results of the Dutch CRS-HIPEC quality registry.接受细胞减灭术联合腹腔热灌注化疗(CRS-HIPEC)治疗的结直肠腹膜转移或假性黏液瘤患者的观察性队列研究:荷兰 CRS-HIPEC 质量登记处的制定和初步结果。
Eur J Surg Oncol. 2024 Dec;50(12):108568. doi: 10.1016/j.ejso.2024.108568. Epub 2024 Aug 14.
7
Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin: A Single Center Experience.细胞减灭术与热灌注腹腔化疗治疗阑尾源性腹膜假黏液瘤:单中心经验
Front Surg. 2021 Aug 26;8:715119. doi: 10.3389/fsurg.2021.715119. eCollection 2021.
8
Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.阑尾来源的假性黏液瘤行细胞减灭术加腹腔内热灌注化疗后的围手术期安全性:单中心 254 例患者的经验。
Eur J Surg Oncol. 2020 Apr;46(4 Pt A):600-606. doi: 10.1016/j.ejso.2020.01.017. Epub 2020 Jan 15.
9
Appendiceal pseudomyxoma peritonei: predictors of recurrence and iterative surgery.阑尾假黏液瘤腹膜假性黏液瘤:复发的预测因素和反复手术。
Colorectal Dis. 2021 Sep;23(9):2368-2375. doi: 10.1111/codi.15778. Epub 2021 Jul 12.
10
The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.腹腔内热灌注化疗在细胞减灭术后假性黏液瘤中的作用。
JAMA Surg. 2021 Mar 1;156(3):e206363. doi: 10.1001/jamasurg.2020.6363. Epub 2021 Mar 10.

本文引用的文献

1
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.细胞减灭术联合腹腔热灌注化疗与单纯细胞减灭术治疗结直肠腹膜转移瘤(PRODIGE 7):一项多中心、随机、开放标签、3 期临床试验。
Lancet Oncol. 2021 Feb;22(2):256-266. doi: 10.1016/S1470-2045(20)30599-4. Epub 2021 Jan 18.
2
Incidence, Risk Factors, and Prevention Strategies for Venous Thromboembolism after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.细胞减灭术和腹腔内热化疗后静脉血栓栓塞症的发生率、危险因素和预防策略。
Ann Surg Oncol. 2019 Jul;26(7):2276-2284. doi: 10.1245/s10434-019-07414-8. Epub 2019 May 7.
3
The Impact of Blood Transfusion on Recurrence and Mortality Following Colorectal Cancer Resection: A Propensity Score Analysis of 4,030 Patients.输血对结直肠癌切除术后复发和死亡的影响:对 4030 例患者的倾向评分分析。
Sci Rep. 2018 Sep 6;8(1):13345. doi: 10.1038/s41598-018-31662-5.
4
Anaesthetic management of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei: a retrospective audit.接受减瘤手术联合腹腔热灌注化疗治疗腹膜假黏液瘤患者的麻醉管理:一项回顾性审计
Anaesth Intensive Care. 2017 Jul;45(4):490-498. doi: 10.1177/0310057X1704500413.
5
Factors associated with thromboembolic events following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.肿瘤细胞减灭术和热灌注化疗后血栓栓塞事件的相关因素。
J Surg Oncol. 2017 Dec;116(7):914-920. doi: 10.1002/jso.24746. Epub 2017 Jun 26.
6
A protocol for management of blood loss in surgical treatment of peritoneal malignancy by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.一项关于通过减瘤手术和腹腔内热灌注化疗治疗腹膜恶性肿瘤手术中失血管理的方案。
Transfus Med. 2016 Apr;26(2):118-22. doi: 10.1111/tme.12301. Epub 2016 Mar 31.
7
A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.一种用于预测减瘤手术联合热灌注腹腔化疗后主要并发症的新型工具。
Ann Surg Oncol. 2016 May;23(5):1609-17. doi: 10.1245/s10434-015-5012-3. Epub 2015 Dec 17.
8
Clinical features of pulmonary emboli in patients following cytoreductive surgery (peritonectomy) and hyperthermic intraperitoneal chemotherapy (hipec), a single centre experience.减瘤手术(腹膜切除术)和腹腔内热灌注化疗(HIPEC)后患者肺栓塞的临床特征:单中心经验
Eur J Surg Oncol. 2015 May;41(5):702-6. doi: 10.1016/j.ejso.2015.01.016. Epub 2015 Jan 30.
9
Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer.低分子量肝素与普通肝素用于癌症患者围手术期的血栓预防
Cochrane Database Syst Rev. 2014 Jun 26(6):CD009447. doi: 10.1002/14651858.CD009447.pub2.
10
Venous thromboembolism prophylaxis in patients undergoing abdominal or pelvic surgery for cancer--a real-world, prospective, observational French study: PRéOBS.癌症患者接受腹部或盆腔手术时的静脉血栓栓塞预防——一项真实世界、前瞻性、观察性的法国研究:PRéOBS
Thromb Res. 2014 Jun;133(6):985-92. doi: 10.1016/j.thromres.2013.10.038. Epub 2013 Nov 1.